DOV Pharmaceuticals says that its back-pain drug failed to hit its primary endpoint in a pivotal trial. None of the three doses tested in the Phase III trial demonstrated a significant improvement over a placebo. Researchers said that the results may have been influenced by an unusually high placebo response rate.
"We are continuing forward with our Phase II trials of bicifadine in osteoarthritis and neuropathic pain and our two Phase III trials of bicifadine in CLBP, studies 021 and 022," says DOV CEO Leslie Hudson. "We will provide more detailed guidance regarding our bicifadine chronic pain program once we are in a position to do so."
- here's the UPI report on the trial results